TB-500

Origin and Structure of TB-500

TB-500 is a synthetic peptide consisting of 43 amino acid residues, corresponding to the active domain of thymosin beta-4 (Tβ4). Thymosin beta-4 is a naturally occurring protein identified in virtually all nucleated cells of vertebrate organisms, with particularly high concentrations observed in platelets. The protein was first characterized by Allan Goldstein's team at George Washington University during research on thymic peptides.

From a structural biochemistry perspective, the key element of the TB-500 sequence is the LKKTETQ domain (residues 17-23), responsible for binding globular actin monomers (G-actin). The peptide features N-terminal acetylation (Ac-), which protects the molecule from aminopeptidase degradation and extends its presence in the research environment. The molecular weight of TB-500 (~4963 Da) is more than three times that of BPC-157 (~1419 Da), resulting in different pharmacokinetic properties in animal models.

Mechanism of Action

The primary mechanism described in the literature is G-actin sequestration. TB-500 binds globular actin monomers in a 1:1 stoichiometric ratio, thereby regulating the dynamics of fibrillar actin (F-actin) polymerization. This process plays a central role in cellular cytoskeleton reorganization, which in in vitro studies on endothelial cell lines translated into enhanced cell migration and lamellipodia formation.

The LKKTETQ domain constitutes the minimal fragment necessary for biological activity of the peptide. In cell cultures, this seven-amino-acid motif has been shown to promote endothelial cell migration and actin fiber reorganization. This mechanism is fundamentally different from the pathways activated by BPC-157, which acts primarily through modulation of the nitric oxide (NO) system and stimulation of VEGF expression.

In animal models (mouse and rat), TB-500 involvement in tissue repair processes has been described, including in cardiac, dermatological, and ophthalmological models. These observations were associated with promotion of cell migration to sites of damage and modulation of inflammatory responses through cytoskeletal regulation of cells engaged in these processes.

Research Overview

Discovery and characterization of thymosin beta-4

A comprehensive review of the discovery and biological functions of thymosin beta-4 was published by Allan Goldstein et al. in 2005 ^[1]. The paper summarizes over three decades of research on this protein, from its isolation from calf thymus, through identification as the major intracellular G-actin-sequestering protein, to animal model studies on tissue repair. The authors described in detail the structure of Tβ4, including the key LKKTETQ actin-binding domain, and discussed tissue distribution of the protein in vertebrates.

Cardiovascular studies

In a landmark paper published in Nature, Bock-Marquette et al. (2004) ^[2] demonstrated that Tβ4 activates integrin-linked kinase (ILK) in mouse cardiomyocytes. In a mouse myocardial infarction model, enhanced cardiac cell migration and reduced damage area were observed. This work represented the first demonstration of Tβ4's role in cardioprotection in an animal model.

Smart et al. (2007) ^[3] published in Nature a study on adult mice demonstrating that Tβ4 reactivates epicardial progenitor cells. In the mouse model, differentiation of these cells toward the vascular lineage was described, suggesting involvement of Tβ4 in neovascularization processes in the adult heart.

Wound healing studies

Malinda et al. (1999) ^[4] conducted some of the first systematic studies on the effect of Tβ4 on wound healing in the rat model. In full-thickness skin wound experiments in rats, accelerated repair processes were observed in the experimental group compared to controls. In vitro studies demonstrated that Tβ4 stimulates keratinocyte and endothelial cell migration, attributed to the LKKTETQ domain-dependent actin cytoskeleton reorganization mechanism.

Corneal studies

Sosne et al. (2002) ^[5] investigated the effects of Tβ4 in rodent corneal injury models (rats and mice). In a series of in vivo experiments, accelerated corneal re-epithelialization was observed following mechanical and chemical damage. In vitro studies on corneal epithelial cell lines confirmed promotion of cell migration by Tβ4, correlating with actin filament reorganization.

References

1. Goldstein AL, et al. "Thymosin beta-4: actin-sequestering protein moonlights to repair injured tissues." Trends in Molecular Medicine. 2005;11(9):421-429.
2. Bock-Marquette I, et al. "Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature. 2004;432:466-472.
3. Smart N, et al. "Thymosin beta-4 induces adult epicardial progenitor mobilization and neovascularization." Nature. 2007;445:177-182.
4. Malinda KM, et al. "Thymosin beta-4 accelerates wound healing." Journal of Investigative Dermatology. 1999;113(3):364-368.
5. Sosne G, et al. "Thymosin beta-4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury." Experimental Eye Research. 2002;74(2):293-299.

Structural Features

TB-500 is a 43-amino acid peptide with a mass of ~4963 Da, characterized by the following features:

• LKKTETQ domain (positions 17-23) — key fragment responsible for G-actin binding and polymerization regulation
• N-terminal acetylation — modification enhancing peptide stability and resistance to exopeptidases
• Methionine residue (Met⁶) — susceptible to oxidation; requires appropriate storage conditions
• Single sulfur atom — in the methionine residue, no disulfide bridges

Przeznaczenie

Produkt jest surowcem chemicznym przeznaczonym wyłącznie do zastosowań badawczych, naukowych i analitycznych in vitro. Nie jest przeznaczony do użytku ludzkiego ani weterynaryjnego, w tym w celach diagnostycznych, terapeutycznych, profilaktycznych lub żywieniowych.

Obchodzenie się z substancją

• Pracuj w warunkach laboratoryjnych zgodnych z zasadami dobrej praktyki laboratoryjnej (GLP).
• Stosuj odpowiednie środki ochrony indywidualnej: rękawice nitrylowe, okulary ochronne, fartuch laboratoryjny.
• Unikaj wdychania pyłu oraz kontaktu ze skórą i błonami śluzowymi.
• Pracuj w dobrze wentylowanym pomieszczeniu.

Klasyfikacja regulacyjna

Produkt nie jest sklasyfikowany jako substancja niebezpieczna zgodnie z rozporządzeniem CLP (WE) nr 1272/2008. Oferowany jest jako odczynnik chemiczny w ramach obowiązujących w Unii Europejskiej przepisów dotyczących substancji chemicznych (REACH, CLP). Nie stanowi produktu leczniczego, suplementu diety, wyrobu medycznego ani kosmetyku w rozumieniu obowiązujących przepisów prawa.

Utylizacja

Substancję niewykorzystaną należy utylizować zgodnie z lokalnymi przepisami dotyczącymi odpadów chemicznych. W warunkach laboratoryjnych: neutralizować i utylizować wraz z odpadami laboratoryjnymi. Nie wylewać do kanalizacji.

Informacje regulacyjne

Produkt oferowany jest zgodnie z obowiązującymi przepisami Unii Europejskiej dotyczącymi substancji chemicznych (REACH, CLP) oraz prawem polskim w zakresie obrotu odczynnikami chemicznymi i materiałami badawczymi. Pełne warunki sprzedaży oraz klasyfikacja produktu zawarte są w Regulaminie Sklepu.

Dokonując zakupu, Klient potwierdza zapoznanie się z powyższymi informacjami oraz akceptuje postanowienia Regulaminu.

Kontakt w sprawach bezpieczeństwa

W przypadku pytań dotyczących obchodzenia się z produktem lub informacji regulacyjnych: kontakt@peptydy-sklep.com.